Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 1, 2010, Pages 115-119

  Jang, S H ^a   Colangelo, P M ^a   Gobburu, J V S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; POSACONAZOLE;

ACUTE LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RASH; SIDE EFFECT; STEADY STATE; SUSPENSION; TREATMENT FAILURE; VOMITING;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GRAFT VS HOST DISEASE; HUMANS; MYCOSES; NEUTROPENIA; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TRIAZOLES;

EID: 77953809369     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.64     Document Type: Article

References (18)

1. Marr, K.A., Carter, R.A., Crippa, F., Wald, A. & Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909-917 (2002). (Pubitemid 34229758)
2. Rotstein, C., Bow, E.J., Laverdiere, M., Ioannou, S., Carr, D. & Moghaddam, N. Randomized placebo-controlled trial of fuconazole prophylaxis for neutropenic cancer patients: beneft based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin. Infect. Dis. 28, 331-340 (1999).
3. Groll, A.H. & Walsh, T.J. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti. Infect. Ther. 3, 467-487 (2005).
4. Ullmann, A.J. et al. Posaconazole or fuconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335-347 (2007).
5. Cornely, O.A. et al. Posaconazole vs. fuconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348-359 (2007).
6. Krishna, G., Martinho, M., Chandrasekar, P., Ullmann, A.J. & Patino, H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27, 1627-1636 (2007).
7. Krishna, G., AbuTarif, M., Xuan, F., Martinho, M., Angulo, D. & Cornely, O.A. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28, 1223-1232 (2008).
8. Gubbins, P.O. et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob. Agents Chemother. 50, 1993-1999 (2006).
9. Krishna, G., Sansone-Parsons, A., Martinho, M., Kantesaria, B. & Pedicone, L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 51, 812-818 (2007).
10. De Pauw, B.E. & Donnelly, J.P. Prophylaxis and aspergillosis-has the principle been proven? N. Engl. J. Med. 356, 409-411 (2007).
11. Noxafl® (Posaconazole) application no. 022003. Clinical Pharmacology and Biopharmaceutics Review(s) http://www.accessdata.fda.gov/drugsatfda-docs/ nda/2006/022003s000-Noxafl-ClinPharmR.pdf (15 September 2006).
12. Bhattaram, V.A. et al. Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81, 213-221 (2007).
13. Walsh, T.J. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44, 2-12 (2007).
14. Courtney, R., Pai, S., Laughlin, M., Lim, J. & Batra, V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47, 2788-2795 (2003).
15. Ezzet, F., Wexler, D., Courtney, R., Krishna, G., Lim, J. & Laughlin, M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44, 211-220 (2005).
16. Krishna, G., Moton, A., Ma, L., Medlock, M.M. & McLeod, J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53, 958-966 (2009).
17. Herbrecht, R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58, 612-624 (2004).
18. Nailor, M.D. & Chandrasekar, P.H. Antifungal drugs: predicting clinical efcacy with pharmacodynamics. Expert Rev. Clin. Pharmacol. 2, 373-379 (2009).